in111-octreoscan
Approved
Jun 2, 1994
An octreotide scan is a type of SPECT scintigraphy used to find carcinoid, pancreatic neuroendocrine tumors, and to localize sarcoidosis. It is also called somatostatin receptor scintigraphy (SRS). Octreotide, a drug similar to somatostatin, is radiolabeled with indium-111, and is injected into a vein and travels through the bloodstream. The radioactive octreotide attaches to tumor cells that have receptors for somatostatin. A gamma camera detects the radioactive octreotide, and makes pictures showing where the tumor cells are in the body, typically by a SPECT technique. A technetium-99m based radiopharmaceutical kit is also available. — Wikipedia
Clinical trial activity
8 trials · 16 clinical orgs · 2 marketing orgs
Earliest trial started Jul 1, 2003 (NCT00944372)
Timeline
1990s
- Jun 2, 1994
Curium Pharma — Earliest FDA Approval
- Jun 2, 1994
Curium Pharma — NDA Secondary Org
- Jun 2, 1994
Curium Pharma — NDA Organization
2000s
- Jan 1, 2005
Earliest Phase 2 Sponsor(trial)
2020s
- Jul 1, 2024
Sun Pharmaceuticals — Marketing Organization
Indications
Approved for
Mechanism of action
- SomatostatinBINDING AGENT
SST binding agent
- Unspecified targetOTHER
Diagnostic agent
Approval history
- approvedPriority reviewJun 2, 1994
Chemistry & pharmacology
- Mol. weight
- 1506.39 g/mol
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
- Multi-specific
- No
- Imaging
- 111-indium
Oral
No
Parenteral
Yes
Topical
No
Sources
- ChEMBLCHEMBL2110556 ↗
- WikipediaOctreotide scan ↗
- ChEMBLCHEMBL1200642 ↗
Also known as
- 111-indium-pentetreotide
- 111 in -pentetreotide
- 111in-pentetreotide
- 111in-pentetreotide
- dtpa-sms
- in111-octreoscan
- in-111 pentetreotide
- in111 pentetreotide
- in111-pentetreotide
- indium (111in) pentetreotide
- indium (111in) pentetreotide
- indium (111in) pentetreotide
- indium in 111 pentetreotide
- indium in 111 pentetreotide
- indium in 111 pentetreotide
- indium in 111 pentetreotide
- indium in-111 pentetreotide
- indium in-111 pentetreotide
- indium in-111 pentetreotide
- indium in-111 pentetreotide kit
- indium in-111 pentetreotide kit
- indium in-111 pentetreotide kit
- indium in 111 pentreotide
- indium in 111 pentreotide
- indium ln-111 pentetreotide
- indium pentetreotide
- indium pentetreotide
- indium-pentetreotide
- mp-1727
- mp-1727
- octreoscan
- octreoscan
- octreoscan
- octreoscan
- octreoscan
- octreoscan 111
- sdz-215811s
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02546388 | N/A | Oct 1, 2015 | Harvard University, Mallinckrodt |
| NCT02465112 | Phase 3 | Sep 1, 2015 | Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR) |
| NCT02078843 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2014 | SWAN Isotopen AG, Bern, University of Bern, University of Lausanne |
| NCT02019706 | Phase 2 | Nov 26, 2013 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH) |
| NCT01869725 | N/A | Apr 1, 2013 | National Cancer Institute (NCI), University of Iowa |
| NCT01099228 | N/A | Sep 30, 2006 | Department of Veteran Affairs, University of Iowa |
| NCT00442533 | Phase 2/Phase 3 (Phase 3) | Aug 1, 2005 | Baylor University, Excel Diagnostic Imaging Clinics, Radio Isotope Therapy of America, RadioMedix, RITA Foundation |
| NCT00944372 | Phase 4 | Jul 1, 2003 | Mallinckrodt |
Organizations
Research & Development (16)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Mallinckrodt | For profit | 2 | 1 | 2 | 2003 |
| University of Iowa | Academic/Hospital | 2 | 2 | 1 | 2006 |
| Baylor University | Academic/Hospital | 1 | 0 | 1 | 2005 |
| Department of Veteran Affairs | Government | 1 | 0 | 1 | 2006 |
| Excel Diagnostic Imaging Clinics | Academic/Hospital | 1 | 0 | 1 | 2005 |
| Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR) | Academic/Hospital | 1 | 1 | 1 | 2015 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2015 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2013 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Government | 1 | 0 | 1 | 2013 |
| National Institutes of Health (NIH) | Government | 1 | 1 | 1 | 2013 |
| Radio Isotope Therapy of America | Academic/Hospital | 1 | 1 | 1 | 2005 |
| RadioMedix | For profit | 1 | 0 | 1 | 2005 |
| RITA Foundation | Academic/Hospital | 1 | 0 | 1 | 2005 |
| SWAN Isotopen AG, Bern | For profit | 1 | 0 | 1 | 2014 |
| University of Bern | Academic/Hospital | 1 | 1 | 1 | 2014 |
| University of Lausanne | Academic/Hospital | 1 | 0 | 1 | 2014 |
Marketing (3)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Curium Pharma | For profit | NDA2 | Jun 2, 1994 |
| Curium Pharma | For profit | NDA | Jun 2, 1994 |
| Sun Pharmaceuticals | For profit | MKTG | Jul 1, 2024 |